Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CEPT1 | Q9Y6K0 | 13/20 | 1.00 |
| ▸ | CETP | P11597 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733919 | 0.91 | CEPT1 (1.00) | CEPT1CETPMAPTRXFP1 | |
| SCHEMBL13676939 | 0.90 | CEPT1 (0.81) | CEPT1CETPMAPTRXFP1 | |
| SCHEMBL1736280 | 0.89 | CEPT1 (0.80) | CEPT1CETPMAPT | |
| SCHEMBL1736218 | 0.88 | CEPT1 (1.00) | CEPT1CETPMAPTRXFP1 | |
| SCHEMBL20768087 | 0.88 | CEPT1 (1.00) | CEPT1CETPMAPT | |
| SCHEMBL1733902 | 0.87 | CEPT1 (0.77) | CEPT1CETPMAPTRXFP1 | |
| SCHEMBL4534132 | 0.87 | CETP (0.86) | CEPT1CETPMAPTRXFP1 | |
| SCHEMBL1734895 | 0.87 | CEPT1 (0.84) | CEPT1CETPMAPTRXFP1 | |
| SCHEMBL12153159 | 0.87 | CEPT1 (0.77) | CEPT1CETPMAPTRXFP1 | |
| SCHEMBL1734909 | 0.86 | CEPT1 (0.82) | CEPT1CETPMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| EP-1954287-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | CEPT1 91/4885CETP 1/4885MAPT 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.